Kamada Discontinues Phase 3 Trial for Genetic Condition, Reiterates Full-Year 2025 Guidance

Kamada Ltd. will discontinue its Phase 3 InnovAATe trial for Alpha-1 Antitrypsin Deficiency (AATD) due to a low likelihood of demonstrating a statistically significant benefit in its primary endpoint. The company reiterated its full-year 2025 revenue guidance of $178-$182 million and adjusted EBITDA guidance of $40-$44 million. Kamada projects double-digit growth in revenues and profitability in 2026 and continues to pursue new commercial stage business development opportunities.